Moderna and Recordati Forge Strategic Alliance to Advance Breakthrough mRNA Therapy for Propionic Acidemia

CAMBRIDGE, MA – January 29, 2026- Moderna, Inc. has entered into a strategic collaboration with the Milan-based pharmaceutical group Recordati to accelerate the clinical development and global commercialization of mRNA-3927. This investigational therapeutic is designed to treat propionic acidemia (PA), a rare and life-threatening metabolic disorder that currently lacks any disease-modifying treatment options. Under the terms of the agreement, Moderna will receive an upfront payment of $50 million, with the potential for an additional $110 million in near-term regulatory and development milestones, plus future royalties.

Propionic acidemia is caused by deficiencies in the propionyl-coenzyme A carboxylase (PCC) enzyme, specifically within the PCCA or PCCB subunits. This deficiency leads to a dangerous accumulation of toxic metabolites, resulting in recurrent metabolic decompensation events and multisystemic complications. mRNA-3927 functions by utilizing mRNA technology to encode for normal human PCCA and PCCB subunits. When administered intravenously, the therapy is intended to restore functional PCC enzymes directly within the patient’s cells, addressing the underlying root cause of the metabolic imbalance.

The partnership leverages Moderna’s leadership in mRNA innovation and Recordati’s extensive commercial infrastructure in the rare disease and metabolic fields. While Moderna continues to spearhead the clinical development of mRNA-3927 through the approval process, Recordati will lead the global commercialization efforts. This synergy is intended to streamline the delivery of the therapy to a global patient population that faces a high mortality rate and significant morbidity.

Currently, mRNA-3927 is being evaluated in a registrational study that has already reached its target enrollment. Interim data from early-phase trials have demonstrated infrequent treatment-limiting side effects and early signs of potential clinical benefit. With a pivotal data readout expected later in 2026, the collaboration focuses on transitioning the program through its final regulatory hurdles to serve the estimated 1 in 100,000 individuals worldwide affected by this condition.